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Although the adaptive immune system has been a focus of research on joint disease over the past
decades, the critical role of innate immunity in the pathogenesis of many autoimmune diseases has
been emphasized only in recent years. Treatment of these autoimmune diseases has been confronted
with many challenges. There is therefore the need to target host pathogenic proteins that influence to
a great extent a number of these autoimmune diseases. High-mobility group box-1 (HMGB1), a
unique and important pathogenic protein, has been implicated as a pro-inflammatory cytokine in the
pathogenesis of various inflammatory and autoimmune diseases. As an important inflammatory
factor, HMGB1 is involved in many cardiovascular diseases, autoimmune disease pathogenesis, and
CD4 T-cell differentiation and modulation. In this review, we will highlight recent evidence
uncovering biological mechanisms of HMGB1 contribution to the pathological process of
autoimmune immune diseases and as well as discuss emerging data on HMGB1 with the aim of
unearthing novel therapeutic targets in autoimmune diseases.
Key Words: autoimmunity, HMGB1, experimental autoimmune encephalitis, rheumatoid arthritis,
experimental autoimmune myocarditis.
INTRODUCTION
Autoimmune diseases are part of the leading causes
of death among young and middle-aged women in
the United States. Within the global population,
autoimmune diseases have become the 3rd leading
cause of morbidity and mortality following
cardiovascular disease and cancer. An estimated 3%
of the population in the United States is affected by a
tissue-specific or systemic autoimmune disorder
(Jacobson, Gange, Rose, & Graham, 1997). However,
incidence rates may vary among the various
autoimmune diseases. Many factors have been
speculated to escalate autoimmune disease risk even
though the cause(s) of autoimmune disorders remain
largely unknown. Considerable evidence supports a
role for environmental agents in inducing
autoimmune disorders (Cooper, Miller, & Germolec,
2002; Hess, 1995). Actually, the approved therapies
of autoimmune diseases initially focused on broad-
based immunosuppression and numerous emerging
therapies undertaking a more targeted
immunomodulatory strategy. All of these strategies
thus aimed to modulate the pathogenic immune
response downstream of the initial oligodendrocyte
damage and innate immune signaling that sustains
the local inflammatory response. Currently, these
immunosuppressive therapies have not been very
impressive and still partly effective. Cytotoxic
treatments including chemotherapy, radiation therapy,
epigenetic drugs, oncolytic viruses, and
immunotherapy, as well as stressed/dying immune
cells often trigger the release of High-mobility group
box-1 (HMGB1) and other pathogenic proteins to
aggravate these autoimmune pathologies. This has
necessitated quick identification of alternative
immunotherapeutic targets to help address this global
issue. An avenue that is receiving much attention and
is being explored for treatment of acute tissue injury
and autoimmunity in other organs targets where the
intrinsic alarm signals or damage associated
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molecular pattern molecules (DAMPs) drives the
local inflammatory response.
HMGB1 was originally defined in some of the most
acute settings of medicine (that is, sepsis, shock)
(Haichao Wang, Bloom, et al., 1999), but its
intriguing immunological properties rapidly
prompted the study of its role in chronic
inflammatory and autoimmune conditions. Since then,
HMGB1 has been implicated as a pro-inflammatory
cytokine in the pathogenesis of various inflammatory
and autoimmune diseases (Klune, Dhupar, Cardinal,
Billiar, & Tsung, 2008). It is known to play an
important role in the development and progression of
autoimmune diseases such as RA (Komiyama et al.,
2006), Myocarditis (Bettelli, Korn, & Kuchroo, 2007)
and Multiple sclerosis (Kimura & Kishimoto, 2010).
Elevated levels of HMGB1 have been found within
the Synovial joints of Rheumatoid arthritis patients
(Kokkola et al., 2002), the heart and serum of
myocarditis patients (Steinman, 2007) as well as in
the CNS and blood of multiple sclerotic patients
(Steinman, 2007). HMGB1 has also been detected in
the tissue and peripheral blood in various tumor
histologies, including breast, colon, gastric,
pancreatic and hepatocellular cancer (Chung et al.,
2009; Kokkola et al., 2002; Kostova, Zlateva,
Ugrinova, & Pasheva, 2010). Approximately one-
third of patients with autoimmune diseases such as
myocarditis, multiple sclerosis, and rheumatoid
arthritis have shown dramatically beneficial response
to the available novel therapies, whilst still a cohort
of patients do not respond appropriately. These
results warrant a search for modulation of additional
inflammatory mediators to improve treatment for all
patients with chronic autoimmune diseases.
Therapeutic neutralization of excessive extracellular
HMGB1 has been speculated to offer a new approach
for managing various inflammatory diseases
including rheumatoid arthritis, myocarditis, multiple
sclerosis and many others. This paper seeks to review
the various roles of HMGB1 in the pathogenesis of
both human and animal disease models of
rheumatoid arthritis, myocarditis and multiple
sclerosis as well as the possibilities of using HMGB1
as a therapeutic target in treatment of the
aforementioned diseases.
Origin & Biochemical Structure of HMGB1
High mobility group (HMG) proteins are a family of
non-histone nuclear proteins that play a role in
transcription, replication, recombination, repair, and
other DNA-associated activities (Hasan & Hottiger,
2002). HMG-1/-2, HMGI/-Y, and HMG-14/-17 are
three subfamilies of HMG proteins (Banks, Li, &
Reeves, 2000; Bustin, 1999). HMGB1 which
belongs to the subfamily of HMG-1/-2, was isolated
three decades ago as an abundant chromosomal
protein with important structural functions in
chromatin organization (Goodwin & Johns, 1973).
Biochemically, HMGB1 is a 30 kDa non-histone,
chromatin-binding protein ubiquitously expressed in
eukaryotic cells and highly preserved across
mammalian species. It contains 215 amino acids and
has a tripartite structure consisting of two DNA-
binding domains, the A box (amino acid residues 9-
79) and the B box (amino acid residues 95-163), and
a C-terminal tail domain (Bianchi, Falciola, Ferrari,
& Lilley, 1992; Müller, Ronfani, & Bianchi, 2004;
Wen, Huang, Johnson, & Gerald, 1989). Unlike
histones, HMGB1 binds to DNA with low affinity
and can move from the nucleus to the cytoplasm
depending upon cell cycle phase (Falciola et al.,
1997). HMGB1 has a unique regional structure in
which different sequences allow interaction with
biochemically disparate molecules (Dintilhac &
Bernués, 2002). The A and B boxes can bind to DNA;
the C-terminal region can bind to histones, while the
C-terminal region can also interact with the A and B
boxes, modifying the 3-dimensional structure of
HMGB1 and its molecular interactions.
Containing three cysteine residues (C23, C45, and
C106) that are redox-sensitive, HMGB1 can be
modified into three isoforms termed “HMGB1” (all-
thiol form), “disulfide HMGB1” (partially oxidized),
and oxidized HMGB1 (Lu et al., 2014; Wu et al.,
2015). The “all-thiol” HMGB1 is known to bind to
other chemokines (e.g., CXCL12) and stimulates
leukocyte recruitment via the CXCR4 receptor
(Venereau, Schiraldi, Uguccioni, & Bianchi, 2013).
The “disulfide” HMGB1 has the ability to activate
immune cells to produce cytokines/chemokines via
TLR4 or other receptors such as RAGE (Venereau et
al., 2013; H. Yang et al., 2015), TLR2, TLR4 (Gill,
Tsung, & Billiar, 2010), TLR9 (Gill et al., 2010; H.
Yang et al., 2015), cluster of differentiation 24
(CD24)/Siglec-10 (H. Yang et al., 2015), Mac-1
(Haichao Wang, Ward, & Sama, 2014),
thrombomodulin (H. Wang et al., 2014), or single
transmembrane domain proteins (e.g., syndecans)
(Lu et al., 2014). During binding to DNA, HMGB1
shows preferences for certain DNA structures such as
bends or cruciforms, consistent with a role in
modifying nucleosomal structure to regulate
transcription, recombination or repair (Cato, Stott,
Watson, & Thomas, 2008; Štros, 2010). The
biological actions of HMGB1 are striking in their
diversity, reflecting the unique biochemistry of this
protein and its propensity for posttranslational
modification.
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Figure 1 The structure of the three isoforms of
HMGB1. HMGB1 exists as oxidized, disulfide and
reduced HMGB1. Structurally, HMGB1 consists of
structure comprising of two DNA-binding domains,
the A box and the B box, and a C-terminal tail
domain which functions as transcription stimulatory
domain. The A box also functions as p53
transactivation domain. The B box serves as TLR4
binding and cytokine activity domains.
Sources and function of HMGB1
HMGB1 can be released through three different
mechanisms: (i) it is actively secreted from
monocytes/macrophages, conventional dendritic cells
(cDC) or pituicytes (Dumitriu et al., 2005; Haichao
Wang, Bloom, et al., 1999; Haichao Wang,
Vishnubhakat, et al., 1999) (ii) it is released
passively from autophagic-stressed cells and (iii) by
necrosis during cancer, injury or inflammation (Sims,
Rowe, Rietdijk, Herbst, & Coyle, 2009).
Functionally, the role of HMGB1 depends on its
location. When inside the nucleus, HMGB1 acts as
an architectural protein that binds to DNA and can
impact transcription. HMBG1 recognizes particular
DNA conformations (e.g., bent DNA) rather than
specific nucleic acid sequences and binds in the
minor groove of the DNA helix. As a result, HMGB1
can distort DNA and thereby enhance interactions
with several proteins, including p53, NF-jB,
progesterone receptors, estrogen receptors and
glucocorticoid receptors (Agresti, Lupo, Bianchi, &
Müller, 2003; Jayaraman et al., 1998). HMGB1 plays
an important role in transcriptional regulation neurite
outgrowth, smooth muscle cell chemotaxis as well as
promoting tumor cell metastasis.
HMGB1 in Experimental Autoimmune
Encephalomyelitis (EAE)
Multiple sclerosis (MS) is an autoimmune-mediated
inflammatory disease of the central nervous system
(CNS) (Polman et al., 2005) characterized by
localized areas with demyelination (Storch et al.,
1998). Experimental Autoimmune Encephalomyelitis
(EAE) is an animal model of MS. This disease is
believed to be an autoimmune disorder mediated by
activated immune cells such as T- and B-
lymphocytes and macrophages/microglia.
Lymphocytes are primed in the peripheral tissues by
antigens, and clonally expanded cells infiltrate the
CNS. HMGB1 is upregulated following brain
ischemia and spinal cord injury (J.-B. Kim et al.,
2006) and in one study it was shown to directly
correlate with neuronal death (Kawabata et al., 2010),
which supports the vital roles of HMGB1 in EAE
disease. There is production of large amounts of
inflammatory cytokines and nitric oxide (NO) that
lead to demyelination and axonal degeneration.
Several studies have shown that oligodendrocytes
(OLGs), the myelin-forming glial cells in the CNS,
are sensitive to cell death stimuli, such as cytotoxic
cytokines, anti-myelin antibodies, NO, and oxidative
stress (Kanwar, 2005). Extranuclear (cytoplasmic)
HMGB1 immunoreactivity has been found to be
expressed in active MS lesions and, conversely,
nuclear HMGB1 immunoreactivity was exhibited in
inactive lesions (Å. Andersson et al., 2008).
Distribution of HMGB1 immunoreactivity suggests
that HMGB1 is released from the cell nucleus when
CNS inflammation occurs.
Previous research by Uzawa et al in 2013 identified
that the protein CSF HMGB1 levels in MS patients
were significantly higher than those in non-
inflammatory neurological diseases patients, (Uzawa
et al., 2013) and these levels in MS patients
correlated with CSF cell counts (Ishizu et al., 2005),
which is also reported by (Yonezu et al., 2014). Thus,
there is a potential interaction among these molecules
in the inflammatory processes involved in EAE and
MS pathogenesis, which thus led to the conclusion
that HMGB1 in the CNS may be a useful biomarker
for CNS inflammation. The first study to demonstrate
that HMGB1 inhibition by a specific monoclonal
antibody could be used for EAE treatment was
performed by Uzawa and his group. They evaluated
the effects of an anti-HMGB1 mouse monoclonal
antibody on EAE development. It was observed that
anti-HMGB1 monoclonal antibody ameliorated the
severity of EAE, as well as attenuated serum IL-17
up-regulation in EAE. It has been reported that
prophylactic treatment with intravenous
immunoglobulin at the time of EAE induction
reduced disease symptoms and the underlying CNS
pathology in EAE (Urbonaviciute et al., 2008).
Uzawa et al. 2013 again found that anti-HMGB1
antibody attenuated CNS inflammation and
demyelination in EAE. Again, treatment with an anti-
HMGB1 monoclonal antibody (20 mg/day for 5 days)
reduced IL-17 production in the peripheral
circulation, which may contribute to the amelioration
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of the clinical and pathological severity of EAE. A
reduction in IL-17 also resulted in the attenuation of
the permeability of the blood–brain barrier,
activation of microglia, suppression of the activity of
matrix metalloproteinase-9 and an immune response
and inflammatory cytokine release by immune cells
such as IL-17, through neutralization of CNS
HMGB1 with a specific antibody (Uzawa et al.,
2013). This monoclonal antibody therapy would be
novel from the perspective that it could be applied
during acute disease exacerbations.
HMGB1 in Experimental Autoimmune
Myocarditis
Myocarditis, which describes inflammatory disorders
of the heart muscle of varied infectious and non-
infectious origins, can lead to dilated
cardiomyopathy (DCM) in young patients.
Unfortunately, myocarditis lacks efficient and
effective treatment. In view of this, more attention
should be directed to the development of efficient
immunomodulatory therapy. A mouse model for this
CD4+ Th cell-mediated post-infectious myocarditis
characterized by the infiltration of inflammatory cells
into the myocardium, cardiomyocytes necrosis and
deposition of collagen by cardiac
fibroblasts/myofibroblasts (Su et al., 2014) is termed
as Experimental autoimmune myocarditis (EAM).
The cytokines and pathogenic proteins secreted by
immune and cardiac cells contribute significantly to
the pathogenesis of this disease in diverse forms. A
previous data showed that HMGB1 was significantly
up-regulated both in heart tissue and blood in EAM
(Su et al., 2011). HMGB1 was found to have
contributed to cardiac fibroblasts/myofibroblasts
proliferation, migration and collagen deposition
leading to EAM progression. It was also
demonstrated that HMGB1 indirectly contributed
Th17 cells expansion by facilitating macrophage
reprogramming M1-like phenotype, but the detailed
mechanisms need to be clarified. For example, M1-
like phenotype macrophages has been observed to
promote naïve CD4+ T cells differentiation into
Th17 cells, effector Th17 cells proliferation or anti-
apoptosis as well as its signal pathway. The same
authors further established that Th17 cells mediated
the EAM development and monocytes/macrophages
infiltrated the heart ((Su et al., 2011; Su et al., 2014).
In this regard, we speculated in our previous article
that the interplay between these cells contribute to
the immunopathogenesis of myocarditis (Amoah,
Yang, Zhang, Su, & Xu, 2015). Over the years, our
research team has published many articles on the
sources and various roles of the pathogenic protein,
HMGB1 in the pathological process of EAM. In this
context, we reported that LPS increases HMGB1
production via TLR4/PI3K signaling pathway, and
again plays a vital role in the LPS-induced
myocardial contractile dysfunction in culture via a
TLR4/PI3K signaling pathway (Xu et al., 2010).
However, cardiac fibroblast /myofibroblast cells can
secrete HMGB1 under stressed conditions (Su et al.,
2014). In agreement, our studies and other reports
have documented elevated levels of HMGB1 protein
in the heart of EAM mice as well as in vitro
proliferation of Th17 with the cells reported to
contribute to the pathogenesis of EAM (Halwani, Al-
Muhsen, Al-Jahdali, & Hamid, 2011; Rayavarapu,
Coley, Kinder, & Nagaraju, 2013; Su et al., 2014).
To further identify whether HMGB1 contributes to
autoimmune myocarditis development, it was
reported that HMGB1 could directly lead to cardiac
fibrosis. In addition, IL-17 secreted by Th17 cells
also could directly lead to cardiac fibrosis. It was
further reported that HMGB1 blockade attenuated
cardiac pathological changes and reduced the number
of infiltrating inflammatory cells in the heart during
EAM (Su et al., 2011). Given the cardio-protective
effects of HMGB1 silencing, inhibition of HMGB1
may improve myocardial fibrosis and undoubtedly
provide new target for its intervention.
HMGB1 in Rheumatoid Arthritis
Rheumatoid arthritis (RA) is characterized by
uncontrolled hyperplastic synovium and
inflammatory synovitis associated with the chronic
production of proinflammatory cytokines and low
oxygen tension. Synovial tissue inflammation in RA
patients is maintained by sustained activation of
multiple inflammatory positive-feedback regulatory
pathways in a variety of cells including myeloid cells.
During RA pathogenesis, it was observed that
HMGB-1 is released from damaged or necrotic cells
and interacts with toll-like receptors (TLRs) and
receptors for advanced glycation end-products
(RAGE) to induce inflammatory signals, as well as
behave as an inflammatory cytokine to activate
innate immune cells. Notably, RAGE interacts with
HMGB-1, advanced glycation end-products, and
innate immune cells to increase local inflammation.
These alarmin proteins when released following cell
damage, interact via TLRs to increase local
inflammation and finally lead to cartilage
degradation (Kokkola et al., 2003). Data from
experimental mice models of arthritis have shown
that HMGB-1 triggers arthritis with the inflammatory
signs of synovitis possibly be neutralized by HMGB-
1-specific monoclonal antibodies (Kokkola et al.,
2003). The potential for HMGB1 to amplify the
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effect of local cytokines has been suggested by its
ability to stimulate macrophages derived from the
synovial fluid of RA patients to release pro
inflammatory cytokines like TNF, IL-1β and IL-6
(Taniguchi et al., 2003).
Intra-articular administration of HMGB1 induces the
onset of arthritis in mice (Pullerits et al., 2003),
suggesting an important role of HMGB1 in the
pathogenesis of the disease (He et al., 2007; Kokkola
et al., 2003). Extranuclear HMGB1 localization has
been described in synovial tissue from osteoarthritis
(OA) patients and in bovine osteoarthritic cartilage
specimens (Hamada et al., 2008; Wähämaa et al.,
2011). Evidence for an active role of HMGB1 in
arthritis pathogenesis is provided by various studies
which have demonstrated that a single injection of
recombinant HMGB1 into knee joints of mice
induced chronic synovitis (Wähämaa et al., 2011).
Neutralization of HMGB1 by treatment with
antibodies or with a specific HMGB1 peptide
antagonist significantly suppressed arthritis
development in several studies (U. Andersson,
Erlandsson-Harris, Yang, & Tracey, 2002; Wähämaa
et al., 2011; Hong Wang et al., 2004). HMGB1
promotes the release of proinflammatory cytokines
(TNF-α, IL-1β, and IL-6) from macrophages in
synovial fluid (Alghasham & Rasheed, 2014; Yan,
Yan, Ramasamy, & Schmidt, 2009). Work by
Hamada et al. (Hamada et al., 2008) depicted that
hypoxia increases extracellular HMGB-1, which
localizes preferentially to regions of tissue hypoxia in
arthritis lesions. HMGB-1 upregulation plays
significant roles in the development of arthritis. It has
been established that synovial inflammation is
accompanied by fibroblast proliferation and
neutrophil infiltration as well as by angiogenesis in
RA patients. The uncontrolled proliferation of the
synovial lining layer leads to microenvironmental
changes resulting in hypoxic conditions (Bosco et al.,
2009; H. Y. Kim et al., 2014). In animal models of
RA, anti-HMGB1 agents confer significant
protection against joint tissue edema (Goldstein et al.,
2007; Kokkola et al., 2003; H. Yang & Tracey, 2010),
supporting a pathogenic role for HMGB1 in
autoimmune diseases.
HMGB1 influences Innate Immune cells during
RA, EAE & EAM
Recent studies have shown associations between
HMGB1 and autoimmune diseases. High HMGB1
levels have been found in RA, Sjögren’s syndrome
(SS), Churg–Strauss syndrome and systemic lupus
erythematosus (SLE) (Ek, Popovic, Erlandsson
Harris, Söderberg Nauclér, & Wahren‐Herlenius,
2006; Taira et al., 2007; Taniguchi et al., 2003).
Important roles of HMGB1 in some autoimmune
diseases have been described with one study
reporting on that HMGB1 and its receptors, namely
RAGE, TLR-2 and TLR-4 were up-regulated in
active lesions of patients with MS and EAE
(Urbonaviciute et al., 2008). The effect of HMGB1
on innate immune cells have been characterized and
well documented. It has been reported to trigger the
maturation of immature cDC, inhibits plasmacytoid
DC response to TLR9 agonists and as well acts as a
chemoattractant for neutrophils and macrophages
(Messmer et al., 2004; Orlova et al., 2007; Popovic et
al., 2006). Furthermore, HMGB1 is known to
promote the survival and adherence of neutrophilic in
addition to eosinophilic granulocytes (Lotfi et al.,
2009). HMGB1 activates monocytes and neutrophils
to release pro-inflammatory cytokines, including
tumour necrosis factor (TNF-α), IL-1β, MIP-1a,
MIP-1b, IL-6 and IL-8 (U. Andersson et al., 2000a;
Park et al., 2003). HMGB1 can induce IL-6 and
TNF-α release from macrophage-like cells (Haichao
Wang, Yang, CZURA, Sama, & Tracey, 2001).
Among its other functions, HMGB1 can also
promote dendritic cell maturation and migration in
vitro (Messmer et al., 2004; D. Yang et al., 2007). It
has also been reported that RAGE and TLR are two
major types of receptors mediating the inflammatory
process triggered by HMGB1 (van Beijnum,
Buurman, & Griffioen, 2008).
Thirteen TLRs (named TLR1 to TLR13) have been
identified in mammalian species (Hans & Hans, 2011;
Rauta, Samanta, Dash, Nayak, & Das, 2014;
Temperley, Berlin, Paton, Griffin, & Burt, 2008).
Actually, TLR4 is the first target activated by
extracellular HMGB1 (U. Andersson & Tracey,
2011). HMGB1-TLR4 pathway can also trigger a
second downstream pathway mediated by TRIF and
leads to activation of type Ⅰ interferon as well as a
delayed activation of NF-κB (Vezzani, Maroso,
Balosso, Sanchez, & Bartfai, 2011), resulting in the
release of cytokine and activation of macrophages.
IL-1β, IL-6 and TNF-α are always released during
the early stage of inflammation. Notably, RAGE is
another important receptor of HMGB1. It is
expressed on a variety of cells, such as monocytes
and belongs to the immunoglobulin superfamily
(Long, 1999; Martìn-Padura et al., 1998). Two major
signaling pathways that are activated by RAGE are
p38 MAPK and ERK1/2 pathways (van Beijnum et
al., 2008). Both pathways can lead to the
phosphorylation and degradation of inhibitors of κB
by IκB kinase and thus activate NF-κB. Activated
NF-κB then transfers to the nucleus and results in
increase in NF-κB DNA binding, expression of
various pro-inflammatory cytokines (e.g., TNF-α, IL-
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1β, IL-6), proliferation of cells and chemotaxis.
HMGB1 can function either as a chemokine to
stimulate leukocyte migration (Bernhagen et al.,
2007; Venereau et al., 2013; D. Yang et al., 2007) or
as a cytokine to activate macrophages (Bernhagen et
al., 2007; Oppenheim & Yang, 2005; Soehnlein &
Lindbom, 2010) and endothelial cells (Bernhagen et
al., 2007; Oppenheim & Yang, 2005) to produce
more cytokines, chemokines, and adhesion molecules.
HMGB1 can mediate inflammation via receptors of
innate immune systems such as TLR and RAGE in
the pathogenesis of many inflammatory diseases
including arthritis (Klune et al., 2008), myocarditis
(Iwasaki & Medzhitov, 2010) and multiple sclerosis
(Blanco, Palucka, Pascual, & Banchereau, 2008).
There is paucity of information about how HMGB1
can influence the complement pathways. Therefore,
investigation into the role of HMGB1 in activation of
complement pathways and other binding receptors is
urgently needed.
The roles of Adaptive immune cells are
modulated in RA, EAE & EAM
The effects of HMGB1 on the function of different
T-cell subsets have still remained elusive. Present
evidence by Wild et al., reports that HMGB1
differentially impacts the biology of conventional
and regulatory T cells. The authors further posited
that HMGB1 is a potent chemoattractant for Treg,
which might contribute to the infiltration and
retention of Treg within damaged tissues (Wild et al.,
2012). The effects of HMGB1 on Treg have been
speculated to have the ability to alter immune
reactivity in the setting of chronic inflammatory
states such as cancer (Allavena & Mantovani, 2012).
HMGB1 is known to modulate the biological
activities of Treg as it can induce migration and
prolongation of Treg survival. HMGB1 enhances
suppressive capacity of T regulatory cells in cancers
in a RAGE-dependent manner. In addition, it directly
suppresses interferon-gamma (IFN-γ) release of
conventional T cells (Tcon) and inhibits their
proliferation via TLR4. It has been reported that
enhanced proliferation of human CD4+ T
lymphocytes is mediated by HMGB1, particularly
when they are activated with limiting concentrations
of aCD3 and aCD28 (Sundberg, Fasth, Palmblad,
Harris, & Andersson, 2009). Additionally, HMGB1
is known to increase the proliferation of Th17 cells
leading to the upregulation of IL-17, as well as lead
to cardiac fibrosis. Endogenous or exogenous
HMGB1 is established to play a role in DC activation
and CD41 T-cell polarization (Su et al., 2011) as
other studies also indicated that HMGB1 secreted by
maturing DCs orchestrated priming, activation, and
polarization of Th1 cells in vitro (Su et al., 2011; S.
Zhang, Zhong, Yang, Gong, & Wang, 2010). Some
studies have described that IL-17 had a predominant
role in MS pathogenesis (Ishizu et al., 2005; Lock et
al., 2002). However, most evidence was derived from
EAE (Komiyama et al., 2006). In addition to IL-17,
IL-6 plays crucial roles in EAE (Eugster, Frei, Kopf,
Lassmann, & Fontana, 1998; Quintana et al., 2009).
In EAM, HMGB1 has been found to indirectly
contribute to Th17 cells expansion (Su et al., 2014).
This confirms the immunomodulatory activities of
HMGB1 on adaptive immune cells.
Therapeutic advances in targeting HMGB1 in
RA, EAE & EAM
Many recent research have proven that targeting
HMGB1 could be an important therapeutic approach
in autoimmune diseases. It is also known that
modification of HMGB1 and its interaction with
various molecules are significant mediators of
signaling pathways, suggesting that HMGB1 can
serve as a new target for therapeutic purposes.
Specific inhibition of endogenous HMGB1 reversed
the lethality of established sepsis therapeutically,
presumably by abrogating HMGB1-induced IL-6 and
TNF-α release from macrophage-like cells (U.
Andersson et al., 2000b). Antagonistic HMGB1
signals, based on small-molecule inhibitors such as
ethyl pyruvate (Albayrak et al., 2010), HMGB1
silencing RAGE or TLRs knockout (Entezari et al.,
2012; He et al., 2007; Leemans et al., 2009) have
proven successful in a wide range of experiments,
thereby resulting in reduced severity of autoimmune
models. Anti-HMGB1 treatment, using HMGB1
antibodies or specific antagonist A box, has shown
beneficial effects in collagen-induced arthritis in
rodents (Kokkola et al., 2003). Therefore, an anti-
HMGB1-based therapeutic strategy may also be
useful in chronic inflammatory diseases such as
arthritis.
Anti-HMGB1 monoclonal antibody therapy partially
prevented joint destruction and exhibited beneficial
anti-arthritic effects in models of arthritis
(Schierbeck et al., 2011), and attenuated cardiac
pathological changes as well as reduced the number
of infiltrating inflammatory cells in the heart
inducted by experimental autoimmune myocarditis
via suppression of T helper type 17 (Th17) cells (Su
et al., 2011). Inhibition of HMGB1 (A-box)
ameliorated the induction of myocardial apoptosis
(Xu et al., 2010). Besides, administration of
HMGB1 dose-dependently increases the expression
of collagens I and III, and TGF-β1, while
pharmacological (neutralizing anti-HMGB1 antibody)
or genetic (shRNA-HMGB1) inhibition of HMGB1
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in cardiac fibroblasts reduces HG-induced collagen
production, MMPs activities, proliferation, and
activates MAPK signaling (W.-k. Wang et al., 2014).
Neutralizing extracellular HMGB1 in CNS with an
anti-HMGB1 monoclonal antibody alleviated
inflammation, which may have resulted in residual
nuclear HMGB1 staining in anti-HMGB1
monoclonal antibody-treated EAE mice spinal cord
sections. It has been reported that prophylactic
treatment with intravenous immunoglobulin at the
time of EAE induction reduced disease symptoms
and the underlying CNS pathology in EAE
(Jorgensen & Sorensen, 2005). Anti-HMGB1
monoclonal antibody therapy has been proven to be
effective in the treatment of brain ischaemia as it
inhibited the permeability of the blood–brain barrier,
the activation of microglia, as well as the expression
of TNF-a and inducible nitric oxide synthase coupled
with its ability to suppress the activity of matrix
metalloproteinase-9 by efficient clearance of
circulating HMGB1 (Liu et al., 2007; J. Zhang et al.,
2011) Further studies are recommended to define the
immunological properties of HMGB1 and optimize
strategies for blocking its abnormal activation in
autoimmune diseases.
FUTURE PERSPECTIVES
HMGB1 is a ubiquitous protein that has diverse roles
in mediating significant pathways of inflammation
within and out of the microenvironment of cells. It
plays a key role in controlling autoimmune responses
by stimulating the release of inflammatory cytokines.
The control of HMGB1 is considered to be a critical
factor in the pathogenesis of many autoimmune
diseases. Anti-HMGB1 monoclonal antibody therapy
could be one of the best therapeutic options in the
treatment of autoimmune diseases especially in this
era where immunotherapy has been proven to be the
best alternative in the treatment of cancers and
autoimmune diseases. Future clinical trials will
therefore help define whether HMGB1 will offer
targets for therapeutic intervention, or whether
targeted modulation of immune responses by
HMBG1 can augment anti-inflammatory counter-
reactions in autoimmune diseases.
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